Incyte Insider Sale Is Routine Tax Move Amid Strong FrontMIND Oncology Results
Incyte’s insider sale of 8,264 shares is a routine tax move, not a warning. With frontMIND Phase‑III data showing 48% response and 12‑month survival over 80%, the tafasitamab–lenalidomide combo looks ready for FDA review, giving investors and clinic…
4 minutes to read